New patent covers combining hTERT and Follistatin-344 to target telomere length, muscle mass and blood-glucose levels in age-related disease.
Patents don’t usually make headlines. This one probably shouldn’t either, except for what it’s protecting. A company just secured legal ground around a strategy that treats aging itself as the target, rather than any single disease that aging happens to produce.
BioViva USA Inc, based in Seattle, announced that the US Patent and Trademark Office issued Patent No. 12,653,907 back in June, titled Methods of Treating or Preventing Age-Related Disorders. The filing covers a combination of two genetic targets, human telomerase reverse transcriptase (hTERT) and Follistatin-344 (FST), used together rather than separately, which turns out to be the interesting part [1].
hTERT will ring a bell for anyone who has read much longevity research. It’s the working half of telomerase, the enzyme responsible for maintaining telomeres, the small protective caps on the ends of chromosomes that shorten a little with every cell division. Shorter telomeres track fairly closely with reduced cellular capacity, and, more loosely, with aging in general. Follistatin-344 operates in a different corner of biology altogether. It’s a protein tied to pathways that govern muscle and tissue function, relevant territory once sarcopenia, the age-related loss of muscle mass, starts to set in.
Put the two together, BioViva’s patent claims specifically name telomere length, muscle mass and blood-glucose levels as outcomes the combination is meant to move. The filing also covers delivery methods, including viral vectors such as adeno-associated virus, or AAV, a fairly established tool at this point for getting genetic material into cells.
Founder and CEO Elizabeth Parrish has built BioViva around a premise that runs against how most biotechs operate. Instead of developing one drug for heart disease and a separate one for muscle wasting, her argument is that both trace back to shared biological processes worth targeting directly.
“This patent represents an important milestone in BioViva’s effort to develop a new category of medicine focused on the biology of aging,” Parrish said. “We have been working for years to develop genetic approaches that address fundamental mechanisms associated with aging. Protecting the combination of hTERT and Follistatin-344 strengthens our ability to advance that work.”
There’s a real case behind that logic, even if it sounds like marketing on first read. Modern medicine mostly treats chronic disease as it shows up, heart disease over here, cognitive decline over there, frailty somewhere else entirely, but a lot of those conditions share roots that develop quietly for decades before any of them get diagnosed. Catch the shared biology earlier, the thinking goes, and the trajectory of several diseases might shift at once rather than one at a time.
“Aging is the greatest risk factor for many of the diseases that ultimately limit human healthspan,” Parrish said. “Our goal is to move medicine upstream, to address the biology that contributes to age-related decline rather than simply treating its consequences one disease at a time.”
None of this means a drug is coming soon. A patent protects intellectual property. It doesn’t approve anything, and BioViva says as much itself: the issuance of the patent does not constitute regulatory approval and does not establish the safety or efficacy of a therapeutic product. The combination remains investigational and still has to clear the usual run of preclinical work, clinical trials and regulatory review before it reaches an actual patient.
Still, it adds to a portfolio that already spans telomere maintenance, tissue regeneration, metabolic regulation and cognitive decline. For a small biotech working in a field short on both breakthroughs and patience, locking down the legal ground around a combination gene therapy is as much a business move as a scientific one, and it says something about where BioViva plans to keep pushing next.
